Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MEMP1972A · 3 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| MEMP1972A 150 mg | EXPERIMENTAL | - |
| MEMP1972A 300 mg | EXPERIMENTAL | - |
| MEMP1972A 450 mg | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| A | EXPERIMENTAL | - |
| B | PLACEBO_COMPARATOR | - |
| C | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| MEMP1972A | DRUG | Subcutaneous repeating dose |
| placebo | DRUG | Subcutaneous repeating dose |
Inclusion Criteria: * Adult patients, 18 to 75 years of age inclusive * Body weight \>/= 40 kg * Physician's diagnosis of asthma for at least 12 months * Evidence of documented bronchodilator reversibility as defined by protocol * Prebronchodilator FEV1 \>/= 40% and \</= 80% predicted at Visit 1 * ...
Top 16 of 18 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 5 | PHASE3 | QVM149, QMF149, Glycopyrronium bromide |
| GSK plc Sponsored ADR | GSK | 10 | PHASE3 | Trelegy Ellipta, Depemokimab, HFA-152a, GSK5784283, Ventolin |
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 4 | PHASE3 | TEV-56248, ProAir (albuterol sulfate eMDPI), Budesonide/Formoterol SPIROMAX, Reslizumab |
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Dupilumab, Lunsekimig |
| AstraZeneca PLC | AZN | 28 | PHASE3 | Benralizumab, Tezepelumab, Budesonide/formoterol, Albuterol/budesonide, PT007 |
| Pfizer Inc. | PFE | 4 | PHASE3 | Tilrekimig, PF-07275315, PF-08103402 |
| Generate Biomedicines, Inc. | GENB | 3 | PHASE3 | GB-0895 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Incyte Corporation | INCY | 1 | PHASE2 | povorcitinib |
| Upstream Bio, Inc. | UPB | 1 | PHASE2 | Verekitug |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE2 | ARO-RAGE |
| Amgen Inc. | AMGN | 1 | PHASE1 | AMG 691 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Apogee Therapeutics, Inc. | APGE | 1 | PHASE1 | APG777 |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE1 | CDX-622 |
MEMP1972A is an investigational small molecule being developed by Roche for respiratory conditions, specifically asthma and allergic rhinitis. It has been studied in patients with allergic rhinitis and in patients with mild asthma, as well as in those with allergic asthma inadequately controlled on inhaled steroids and a second controller.
MEMP1972A is being developed by Roche Holding AG, which trades under the ticker RHHBY. The drug is an investigational small molecule in clinical development for respiratory indications including asthma and allergic rhinitis.
MEMP1972A is in clinical development. While its earliest trial was Phase 1, later trials were Phase 2. All three trials listed for MEMP1972A are completed, and the drug remains investigational, meaning it is not approved and is still being studied for asthma and allergic rhinitis.
MEMP1972A has been studied in three completed trials: NCT01160861, a Phase 1 study in allergic rhinitis; NCT01196039, a Phase 2 study in mild asthma; and NCT01582503, a Phase 2 study in allergic asthma. These trials enrolled a total of 607 participants.
MEMP1972A is the sole name provided for this investigational drug. No alternative names have been identified in the available information. The drug is being studied under this identifier in clinical trials for asthma and allergic rhinitis.